NASDAQ:CLRB - Cellectar Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.9550 +0.03 (+3.24 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.9550
Today's Range$0.9001 - $0.98
52-Week Range$0.84 - $2.06
Volume110,282 shs
Average Volume264,898 shs
Market Capitalization$16 million
P/E Ratio-0.89
Dividend YieldN/A
Beta0.74

About Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences logoCellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. In addition, the company is developing CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX product candidates, which are in pre-clinical research for the treatment of chemotherapy. It has strategic collaboration with Onconova Therapeutics, Inc. to develop phospholipid drug conjugates. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64

Price-To-Earnings

Trailing P/E Ratio-0.89
Forward P/E Ratio-1.35
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-13,560,000.00
Net MarginsN/A
Return on Equity-178.37%
Return on Assets-139.16%

Miscellaneous

Employees15
Outstanding Shares17,390,000

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) released its quarterly earnings results on Friday, May, 11th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. View Cellectar Biosciences' Earnings History.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:
  • Mr. James V. Caruso, CEO, Pres & Director (Age 59)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 45)
  • Mr. Brian M. Posner, CFO & VP (Age 56)
  • Dr. John E Friend II, M.D., Chief Medical Officer and VP (Age 48)
  • Gregory J. Lynch, Sec.

Has Cellectar Biosciences been receiving favorable news coverage?

News articles about CLRB stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a media sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $0.9550.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $16 million. The biopharmaceutical company earns $-13,560,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]


MarketBeat Community Rating for Cellectar Biosciences (CLRB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellectar Biosciences (NASDAQ:CLRB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$2.70
Price Target Upside: N/AN/AN/A117.74% upside

Cellectar Biosciences (NASDAQ:CLRB) Consensus Price Target History

Price Target History for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ:CLRB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2016Ladenburg ThalmannInitiated CoverageBuy$2.70N/AView Rating Details
12/21/2016Langenberg & CompanyInitiated CoverageBuy$2.70N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Cellectar Biosciences (NASDAQ:CLRB) Earnings History and Estimates Chart

Earnings by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ:CLRB) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS

Cellectar Biosciences (NASDAQ CLRB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018N/AView Earnings Details
5/11/2018Q1 2018($0.20)($0.21)ViewN/AView Earnings Details
3/21/2018Q4 2017($0.23)($0.34)ViewListenView Earnings Details
11/9/2017Q3 2017($0.25)($0.26)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.24)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.23)($0.35)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.20)($0.43)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.40)($0.49)ViewN/AView Earnings Details
5/12/2016Q1 2016$0.91ViewN/AView Earnings Details
11/12/2015Q315($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.30)ViewListenView Earnings Details
5/21/2015Q115($0.30)ViewListenView Earnings Details
3/24/2015Q4 2014($2.20)ViewN/AView Earnings Details
11/11/2014Q3 2014($1.00)ViewN/AView Earnings Details
8/20/2014Q2 2014($6.60)ViewN/AView Earnings Details
5/14/2014Q1 2014($10.00)ViewN/AView Earnings Details
3/25/2014Q4 2013($8.00)($10.00)ViewN/AView Earnings Details
11/6/2013Q3 2013($10.00)($14.00)$92.67 millionViewN/AView Earnings Details
8/12/2013Q2 2013($10.00)($10.00)ViewN/AView Earnings Details
5/15/2013Q1 2013($8.00)($12.00)ViewN/AView Earnings Details
5/4/2012Q1 2012($12.00)($11.80)ViewN/AView Earnings Details
3/9/2012Q4 2011($12.00)ViewN/AView Earnings Details
11/7/2011Q3 2011($14.20)ViewN/AView Earnings Details
8/18/2011Q2 2011($20.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cellectar Biosciences (NASDAQ:CLRB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cellectar Biosciences (NASDAQ CLRB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.74%
Institutional Ownership Percentage: 2.50%
Insider Trading History for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ CLRB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Jarrod LongcorInsiderSell13,000$1.18$15,340.0067,000View SEC Filing  
3/12/2018James V CarusoCEOSell34,000$1.20$40,800.00213,548View SEC Filing  
11/14/2017John NeisDirectorSell5,214$1.49$7,768.86View SEC Filing  
11/29/2016John NeisDirectorBuy333,333$1.49$496,666.17View SEC Filing  
10/31/2016Richard HertzbergInsiderSell21,000$2.03$42,630.00280,000View SEC Filing  
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.7647,548View SEC Filing  
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52117,371View SEC Filing  
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.006,000View SEC Filing  
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.005,000View SEC Filing  
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.004,000View SEC Filing  
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cellectar Biosciences (NASDAQ CLRB) News Headlines

Source:
DateHeadline
Cellectar Biosciences (CLRB) Upgraded by Zacks Investment Research to BuyCellectar Biosciences (CLRB) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 18 at 7:47 PM
Zacks Investment Research Lowers Cellectar Biosciences (CLRB) to HoldZacks Investment Research Lowers Cellectar Biosciences (CLRB) to Hold
www.americanbankingnews.com - May 17 at 8:08 PM
Cellectar Biosciences (CLRB) Releases  Earnings Results, Misses Estimates By $0.01 EPSCellectar Biosciences (CLRB) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 12 at 11:15 AM
Cellectar Biosciences (CLRB) Misses Q1 EPS by 1cCellectar Biosciences (CLRB) Misses Q1 EPS by 1c
www.streetinsider.com - May 11 at 10:24 AM
Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial ResultsCellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results
finance.yahoo.com - May 11 at 10:24 AM
Cellectar Biosciences (CLRB) Says it Was Granted FDA Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaCellectar Biosciences (CLRB) Says it Was Granted FDA Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
www.streetinsider.com - May 9 at 4:30 PM
Cellectar Bios CLR 131 an Orphan Drug in U.S. for rare type of pediatric cancer; shares up 4%Cellectar Bio's CLR 131 an Orphan Drug in U.S. for rare type of pediatric cancer; shares up 4%
seekingalpha.com - May 9 at 4:30 PM
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaCellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
finance.yahoo.com - May 9 at 4:30 PM
Cellectar Biosciences (CLRB) Upgraded to "Hold" by ValuEngineCellectar Biosciences (CLRB) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM
Cellectar Bios CLR 131 nabs rare pediatric disease tag in U.S., shares up 5% premarketCellectar Bio's CLR 131 nabs rare pediatric disease tag in U.S., shares up 5% premarket
seekingalpha.com - May 2 at 9:25 AM
Cellectar Biosciences (CLRB) Receives FDA Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaCellectar Biosciences (CLRB) Receives FDA Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
www.streetinsider.com - May 2 at 9:25 AM
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on WednesdayCellectar Biosciences (CLRB) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:50 AM
Cellectar Biosciences (CLRB) Presents Preclinical Data at AACR Demonstrating Efficacy of Fractionated Injections of ...Cellectar Biosciences (CLRB) Presents Preclinical Data at AACR Demonstrating Efficacy of Fractionated Injections of ...
www.streetinsider.com - April 19 at 9:29 AM
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple MyelomaCellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma
finance.yahoo.com - April 17 at 9:50 AM
Cellectar Biosciences (CLRB) Says Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of its CLR ...Cellectar Biosciences (CLRB) Says Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of its CLR ...
www.streetinsider.com - April 16 at 9:23 AM
Cellectar Biosciences (CLRB) Downgraded to "Hold" at Zacks Investment ResearchCellectar Biosciences (CLRB) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:10 PM
Cellectar Biosciences (CLRB) Upgraded to Buy by Zacks Investment ResearchCellectar Biosciences (CLRB) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 5 at 8:30 PM
New finance chief at Cellectar BioNew finance chief at Cellectar Bio
seekingalpha.com - April 4 at 5:05 PM
Cellectar Biosciences Appoints Brian M. Posner as Chief Financial OfficerCellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer
finance.yahoo.com - April 4 at 5:05 PM
Cellectar (CLRB) Reports Issuance of U.S. Patent Covering CLR 131 Use in Multiple MyelomaCellectar (CLRB) Reports Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
www.streetinsider.com - April 3 at 9:48 AM
Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple MyelomaCellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
finance.yahoo.com - April 3 at 9:48 AM
Cellectar Biosciences (CLRB) Secures U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug VehiclesCellectar Biosciences (CLRB) Secures U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
www.streetinsider.com - March 28 at 9:45 AM
Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug VehiclesCellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
finance.yahoo.com - March 27 at 9:59 AM
Cellectar Biosciences (CLRB) Upgraded to "Sell" by ValuEngineCellectar Biosciences (CLRB) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM
Cellectar Reports 2017 Financial Results and Provides a Corporate ... - NasdaqCellectar Reports 2017 Financial Results and Provides a Corporate ... - Nasdaq
www.nasdaq.com - March 22 at 4:23 PM
Cellectar Biosciences (CLRB) Posts  Earnings Results, Misses Estimates By $0.11 EPSCellectar Biosciences (CLRB) Posts Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - March 22 at 12:29 PM
Cellectar BioSciences, Inc. to Host Earnings CallCellectar BioSciences, Inc. to Host Earnings Call
finance.yahoo.com - March 22 at 9:45 AM
Cellectar Reports 2017 Financial Results and Provides a Corporate Update - GlobeNewswire (press release)Cellectar Reports 2017 Financial Results and Provides a Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:24 PM
Cellectar Reports 2017 Financial Results and Provides a Corporate UpdateCellectar Reports 2017 Financial Results and Provides a Corporate Update
finance.yahoo.com - March 21 at 4:24 PM
Cooper Companies (COO) vs. Cellectar Biosciences (CLRB) Head to Head ReviewCooper Companies (COO) vs. Cellectar Biosciences (CLRB) Head to Head Review
www.americanbankingnews.com - March 21 at 3:25 PM
Earnings Scheduled For March 21, 2018 - BenzingaEarnings Scheduled For March 21, 2018 - Benzinga
www.benzinga.com - March 21 at 10:40 AM
Benzinga Pros 5 Stocks To Watch Today (CSRA)(BCS)(ORCL ... - BenzingaBenzinga Pro's 5 Stocks To Watch Today (CSRA)(BCS)(ORCL ... - Benzinga
www.benzinga.com - March 19 at 4:20 PM
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018
finance.yahoo.com - March 19 at 9:41 AM
Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat NeuroblastomaCellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
finance.yahoo.com - March 19 at 9:41 AM
Cellectar (CLRB) Reports Late-Breaking Poster Presentations at AACR - StreetInsider.comCellectar (CLRB) Reports Late-Breaking Poster Presentations at AACR - StreetInsider.com
www.streetinsider.com - March 17 at 9:43 AM
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
finance.yahoo.com - March 15 at 9:24 AM
Insider Selling: Cellectar Biosciences Inc (CLRB) Insider Sells 13,000 Shares of StockInsider Selling: Cellectar Biosciences Inc (CLRB) Insider Sells 13,000 Shares of Stock
www.americanbankingnews.com - March 14 at 4:33 PM
Cellectar Biosciences Inc (CLRB) CEO Sells $40,800.00 in StockCellectar Biosciences Inc (CLRB) CEO Sells $40,800.00 in Stock
www.americanbankingnews.com - March 14 at 4:32 PM
Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and BiologyPhase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology
finance.yahoo.com - March 6 at 9:19 AM
Cellectar Biosciences (CLRB) Set to Announce Earnings on TuesdayCellectar Biosciences (CLRB) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
Cellectar Biosciences to Present at Upcoming March Conferences - GlobeNewswire (press release)Cellectar Biosciences to Present at Upcoming March Conferences - GlobeNewswire (press release)
globenewswire.com - March 5 at 9:44 AM
Cellectar Biosciences to Present at Upcoming March ConferencesCellectar Biosciences to Present at Upcoming March Conferences
finance.yahoo.com - March 5 at 9:44 AM
Cellectar Biosciences (CLRB) Presents At BIO CEO & Investor Conference - SlideshowCellectar Biosciences (CLRB) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:27 PM
Cellectar Biosciences to Present at the 2018 BIO CEO & Investor ConferenceCellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 8:55 AM
biotechstocks.com: 2 Biotech Stocks to Watch This Quarterbiotechstocks.com: 2 Biotech Stocks to Watch This Quarter
www.finanznachrichten.de - January 29 at 4:25 PM
2 Biotech Stocks to Watch This Quarter2 Biotech Stocks to Watch This Quarter
finance.yahoo.com - January 29 at 4:25 PM
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic CancersCellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
finance.yahoo.com - January 29 at 9:14 AM
How Much is Cellectar Biosciences Inc’s (NASDAQ:CLRB) CEO Getting Paid?How Much is Cellectar Biosciences Inc’s (NASDAQ:CLRB) CEO Getting Paid?
finance.yahoo.com - January 24 at 9:34 AM
Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor ConferenceCellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference
finance.yahoo.com - January 22 at 5:49 PM
Reviewing Veru (VERU) & Cellectar Biosciences (CLRB)Reviewing Veru (VERU) & Cellectar Biosciences (CLRB)
www.americanbankingnews.com - January 20 at 11:30 PM

SEC Filings

Cellectar Biosciences (NASDAQ:CLRB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellectar Biosciences (NASDAQ:CLRB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellectar Biosciences (NASDAQ CLRB) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.